Sort   by:  
 Page size 
TranscriptomicsExpression of SUDHL-1 cell line treated by ALK inhibitors
In this study we compared the effects of ALK inhibitor on the gene expression, activation of cell signaling pathways, and functional properties of cells derived from a patient with Anaplastic Large Cell Lymphoma. we used microarrays to map the genome-wide gene expression patterns in ALK+TCL cells in...
ORGANISM(S): Homo sapiens 
2013-10-31 | E-GEOD-50803 | biostudies-arrayexpress
TranscriptomicsRegulation of gene expression in ALK inhibitor CH5424802-treated NCI-H2228 xenograft tumors
To clarify the downstream signal pathway of EML4-ALK in NSCLC, we performed Affymetrix GeneChip analysis using ALK inhibitor CH5424802-treated NCI-H2228 xenograft tumors, and comprehensively characterized the gene expression regulated by inhibition of activated ALK. Mice bearing NCI-H2228 cells were...
ORGANISM(S): Mus musculus 
2011-06-03 | E-GEOD-25118 | biostudies-arrayexpress
ProteomicsDisruption of the ALK tumor cell proteome by concurrent inhibition of ALK and SRC kinases.
Precision oncology has revolutionized the treatment of ALK-positive lung cancer with targeted therapies. However, refractory tumors with compound mutations or diverse resistance mechanisms remain an unmet clinical need. In this study, we established mouse tumor-derived cell models representing the m...
ORGANISM(S): Mus musculus (Mouse) 
2024-04-11 | PXD043012 | Pride
Eml4-alk Precision oncology Non-small cell lung cancer (nsclc) Tyrosine kinase inhibitors (tkis) (phospho)proteomic 
ProteomicsALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression
Anaplastic lymphoma kinase (ALK) fusion variants in non-small-cell-lung cancer (NSCLC) consist of numerous dimerising fusion partners, with the most common being EML4. Clinical data suggests that the degree of treatment benefit in response to ALK tyrosine kinase inhibitors (TKIs) differs among the v...
ORGANISM(S): Homo sapiens (Human) 
2023-02-16 | PXD035100 | Pride
Human Nsclcl Orbitrap fusion lumos 
ProteomicsALK signalling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition
High-risk neuroblastoma (NB) currently presents significant clinical challenges. MYCN and ALK, which are often involved in high-risk NB, lead to increased replication stress in cancer cells, providing options for therapeutic exploitation. We previously identified an ATR/ALK inhibitor combination as ...
ORGANISM(S): Homo sapiens (Human) 
2023-12-13 | PXD041824 | Pride
Alk Atr Elimusertib Neuroblastoma Lorlatinib Alkal Ddr Ceralasertib 
ProteomicsDisruption of the ALK tumor cell proteome by concurrent inhibation of ALK and SRC kinases
Precision oncology has revolutionized the treatment of ALK-positive lung cancer with targeted therapies. However, refractory tumors with compound mutations or diverse resistance mechanisms remain an unmet clinical need. In this study, we established mouse tumor-derived cell models representing the m...
ORGANISM(S): Mus musculus (Mouse) 
2024-04-11 | PXD042728 | Pride
(phospho)proteomics Eml4-alk Precision oncology Tyrosine kinase inhibitor (tkis) Non-small cell lung cancer (nsclc) 
ProteomicsATR inhibition enables complete tumour regression in ALK-driven NB mouse models
High-risk neuroblastoma (NB) often involves amplification of the neural MYC (MYCN) oncogene as well as mutations in ALK. Currently, high-risk NB presents significant clinical challenges, and additional therapeutic options are needed. Oncogenes such as MYCN and ALK result in increased replication str...
ORGANISM(S): Homo sapiens (Human) 
2021-11-02 | PXD027187 | Pride
Neuroblastoma Atr inhibitor Phosphorylation Alk 
TranscriptomicsTranscriptomic profiling of three different neuroblastoma cell lines (CLB-BAR, CLB-GE and SK-N-AS) in response to ALK inhibition
Anaplastic Lymphoma Kinase (ALK) is a tyrosine kinase receptor which is a clinical target of major interest in cancer, including neuroblastoma. To better understand ALK signaling, three different neuroblastoma cell lines (CLB-BAR, CLB-GE and SK-N-AS) were cultured for 1hr and 24hrs in control condit...
ORGANISM(S): Homo sapiens 
2018-09-01 | E-MTAB-6654 | biostudies-arrayexpress
ProteomicsPhosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cells lines reveals conserved oncogenic pathways
Neuroblastoma is a neural crest-derived embryonal tumor or the postganglionic sympathetic nervous system. Neuroblastomas show heterogeneous biologic and clinical features and , whereas a subset may undergo spontaneous differentiation or regression with little or no therapy, the majorities are diffic...
ORGANISM(S): Homo sapiens (Human) 
2018-11-27 | PXD011187 | Pride
Alk inhibition Oncogenic Neuroblastoma Phosphoproteome Pathways 
TranscriptomicsmRNA expression profiles of SK-N-AS neuroblastoma cells with induced ALK-wt, ALK-F1174L or ALK-R1275Q
Establishment of inducible SK-N-AS ALKwt, ALKF1174L and ALKR1275Q cell lines Human neuroblastoma SK-N-AS cells were electroporated with pcDNA6/TR (Invitrogen) using the NeonM-eM-( Transfection System (Life Techologies). Single cell clones were generated using blasticidin (7.5M-eM-5g/ml) and limited ...
ORGANISM(S): homo sapiens 
2015-05-04 | E-MTAB-3207 | biostudies-arrayexpress
Sort   by:  
 Page size